Why Are NHS Medical Cannabis Prescriptions Limited to Specific Indications?

In recent years, medical cannabis has emerged as a topic of growing interest in the UK healthcare landscape. While cannabis-based products for medicinal use (CBPMs) have been legally prescribable on the NHS since November 2018, access remains tightly regulated and limited to very specific indications. Many patients and even some private clinics find this regulatory environment confusing, especially in light of medical cannabis patient pathway flourishing private market offerings and the use of new technologies like video consultations and remote prescribing.

This post unpacks the key reasons behind the NHS restrictions on medical cannabis prescriptions, carefully distinguishing legality from real-world access. We’ll also explore who is authorised to prescribe, the role of the Care Quality Commission (CQC) in oversight—especially around remote consultations in England—and why transparency about pricing in private clinics is critical. Our goal is to clear up common misconceptions and offer a grounded checklist for patients considering medical cannabis as a treatment option.

Legality vs Real-World Access: Understanding the NHS Position

The legal framework established in 2018 allows specialist doctors on the General Medical Council (GMC) Specialist Register to prescribe cannabis-based medicines. This landmark change was welcomed by many, but it did not translate into broad NHS availability. The reason? A cautious approach based on clinical evidence, funding constraints, and governance concerns.

Specific Indications Allowed on the NHS

Currently, NHS prescriptions for medical cannabis are limited to a small set of conditions where clinical evidence is robust enough and cost-effective funding grounds exist. These include:

• Severe, treatment-resistant epilepsy syndromes in children (e.g., Dravet syndrome, Lennox-Gastaut syndrome)
• Multiple sclerosis (MS) spasticity that has not responded to other treatment options
• Chemotherapy-induced nausea and vomiting unresponsive to standard treatments

The National Institute for Health and Care Excellence (NICE) and NHS England recommend cannabis-based medicines only for these carefully selected cases due to the limited high-quality evidence supporting broader use. The cautious approach results in nhs prescriptions limited to these specific indications, despite widespread public demand for more liberal access.

Funding Gap: NHS Constraints vs Private Market Reality

One major factor limiting NHS prescriptions is the cost. Unlike many licensed medications, cannabis-based products often come with a high price tag, impacting the NHS's budget if prescribed widely. NHS England is under intense financial pressure managing many competing priorities, and medical cannabis does not yet have broad evidence of cost-effectiveness across a wide range of conditions.

As a result, a funding gap opens up. Patients not meeting NHS criteria often turn to the private sector, where clinics provide access outside the NHS remit. However, this comes with significant differences:

• Cost: Private consultations and prescriptions usually involve substantial fees.
• Prescribing authority: Only GMC Specialist Register doctors can prescribe legally; some private clinics fail to clarify this properly.
• Consultation formats: Video consultations are common, especially since they enable remote prescribing, but must comply with CQC rules in England.

Despite increased private market availability, it is important to understand that legality remains unchanged. Having a cannabis prescription on the private market depends on evaluation by an appropriate specialist following professional guidelines and legislation.

Who Can Legally Prescribe Medical Cannabis and Why?

Specified by law and NHS policy, only doctors registered on the GMC Specialist Register can prescribe medical cannabis. This restriction safeguards patient safety and ensures prescriptions are based on rigorous assessment by clinicians with relevant expertise.

The Role of the GMC Specialist Register

The GMC Specialist Register is a list of doctors accredited as specialists in medical fields such as neurology, pain management, paediatrics, or oncology. Their expertise relates directly to the specific indications where medical cannabis is permitted.

GPs and other general practitioners cannot issue cannabis prescriptions unless they also appear on the Specialist Register. This limitation is significant because it explains why many family doctors will refer patients to secondary care specialists rather than prescribing cannabis themselves.

Why This Matters

• Ensures clinical competence: Specialists are trained to weigh benefits vs risks carefully.
• Aligns with evidence: Specialists more likely to follow evolving guidelines grounded in research.
• Protects patient safety: Medical cannabis has psychoactive components requiring careful monitoring.

Video Consultations and Remote Prescribing: The England Context and CQC Oversight

Technological advances have transformed private medical cannabis prescribing. Video consultations enable remote assessment, and doctors can prescribe cannabis preparations without face-to-face visits. While this convenience expands access, it also introduces new regulatory considerations.

The Care Quality Commission (CQC) Role

In England, clinics offering remote medical cannabis statement of purpose CQC consultations and prescribing must notify and register these services with the CQC. This ensures:

• Standards of care are maintained despite the remote format
• Patient safety requirements are met
• Prescribing protocols adhere to legislation and professional guidance

Providers must display CQC registration details openly on their websites or literature for transparency. Patients should verify this before committing to remote prescribing services.

Key Considerations for Remote Prescribing

1. The consultation must be comprehensive despite being remote, assessing history and suitability carefully.
2. Follow-up care plans should be established, ideally with communication lines to NHS or local healthcare providers.
3. Prescriptions must come from appropriately qualified specialists and sent to registered pharmacies.

These safeguards are crucial to prevent risks of inappropriate prescribing or patient misunderstanding.

Addressing a Common Mistake: Transparency on Consultation and Prescription Pricing

Many private clinics offering medical cannabis fall short of clearly stating their prices upfront. This lack of transparency is a problem for patients budgeting for treatment and comparing options.

What You Should Expect

• Consultation Fees: These vary but should be clearly communicated before booking. Some clinics charge for initial assessments; others include follow-up consultations in package deals.
• Prescription Costs: Cannabis-based medicines are not standard NHS drugs, so patients pay for the product and dispensing fees separately. Know the costs of different formulations and typical monthly supply expenses.
• Follow-Up and Monitoring: Ask if ongoing support calls or medical reviews are included or billable.
• Add-On Services: Beware of clinics blending healthcare with wellness or lifestyle marketing—focus on licensed medicines with clear prescribing oversight.

Full pricing transparency protects patients from unexpected bills and supports informed decision-making.

Summary Checklist: Navigating Medical Cannabis Prescriptions in the UK

Key Point What You Should Know NHS Access Limited to specific indications with good evidence; costs and funding are restrictive. Legal Prescribers Only GMC Specialist Register doctors can prescribe medical cannabis legally. Private Clinics Private prescriptions require specialist assessment; expect clear prices and CQC registration (England). Remote Consultations Video consultations can be legitimate but must comply with CQC oversight; check clinic transparency. Pricing Transparency Get upfront details on consultation and prescription costs before committing. Funding Gap Limits broad NHS prescribing, driving demand for private sector solutions.

Conclusion

While the legal framework supports medical cannabis prescriptions in the UK, nhs prescriptions are limited due to careful consideration of clinical evidence and funding priorities. This explains the tightly defined specific indications allowed under the NHS and why many patients explore private options instead. The funding gap remains a key barrier, maintaining a divide between legal medical access and practical availability.

Understanding who can prescribe—exclusively doctors on the GMC Specialist Register—alongside regulatory oversight by the CQC in England, helps patients make safer, informed choices. Transparency on consultation and prescription fees should be a red line for anyone considering private medical cannabis treatment. Moving forward, ongoing research and policy changes may adjust access, but for now, clarity about NHS limitations and private market realities is essential.